Abstracts Featuring Exelixis Compounds Accepted for Presentation at the 2009 AACR-NCI-EORTC International Conference:
Links to data available at time of presentation.
| Abstract Number |
Abstract
Title |
Presentation
Date & Time |
| A254 |
A phase 1 safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor, XL765 (SAR245409), in combination with erlotinib in patients (pts) with advanced solid tumors
Data
|
Monday, November 16
12:30 – 2:30 pm ET |
| A55 |
A first-in-human, phase 1 study of an oral hedgehog pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors
Data
|
Monday, November 16
12:30 – 2:30 pm ET |
| B247 |
A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients with advanced solid tumors
Data
|
Tuesday, November 17
12:30 – 2:30 pm ET |
| B265 |
A phase 1 safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with malignant glioma
Data
|
Tuesday, November 17
12:30 – 2:30 pm ET |
| C197 |
A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients with advanced solid tumors
Data
|
Wednesday, November 18
12:30 – 2:30 pm ET |
